Abstract

ObjectivesTo evaluate CT-derived radiomics for machine learning-based classification of thymic epithelial tumor (TET) stage (TNM classification), histology (WHO classification) and the presence of myasthenia gravis (MG).MethodsPatients with histologically confirmed TET in the years 2000–2018 were retrospectively included, excluding patients with incompatible imaging or other tumors. CT scans were reformatted uniformly, gray values were normalized and discretized. Tumors were segmented manually; 15 scans were re-segmented after 2 weeks by two readers. 1316 radiomic features were calculated (pyRadiomics). Features with low intra-/inter-reader agreement (ICC<0.75) were excluded. Repeated nested cross-validation was used for feature selection (Boruta algorithm), model training, and evaluation (out-of-fold predictions). Shapley additive explanation (SHAP) values were calculated to assess feature importance.Results105 patients undergoing surgery for TET were identified. After applying exclusion criteria, 62 patients (28 female; mean age, 57±14 years; range, 22–82 years) with 34 low-risk TET (LRT; WHO types A/AB/B1), 28 high-risk TET (HRT; WHO B2/B3/C) in early stage (49, TNM stage I-II) or advanced stage (13, TNM III-IV) were included. 14(23%) of the patients had MG. 334(25%) features were excluded after intra-/inter-reader analysis. Discriminatory performance of the random forest classifiers was good for histology(AUC, 87.6%; 95% confidence interval, 76.3–94.3) and TNM stage(AUC, 83.8%; 95%CI, 66.9–93.4) but poor for the prediction of MG (AUC, 63.9%; 95%CI, 44.8–79.5).ConclusionsCT-derived radiomic features may be a useful imaging biomarker for TET histology and TNM stage.

Highlights

  • Thymic epithelial tumors (TET) are the most common primary tumor of the anterior mediastinum in adults and include thymomas, thymic carcinomas (TC) and thymic neuroendocrine tumors

  • 62 patients (28 female; mean age, 57±14 years; range, 22–82 years) with 34 low-risk TET (LRT; World Health Organization (WHO) types A/AB/B1), 28 high-risk TET (HRT; WHO B2/B3/C) in early stage (49, TNM stage I-II) or advanced stage (13, TNM III-IV) were included. 14(23%) of the patients had myasthenia gravis (MG). 334(25%) features were excluded after intra-/inter-reader analysis

  • Discriminatory performance of the random forest classifiers was good for histology(AUC, 87.6%; 95% confidence interval, 76.3–94.3) and TNM stage(AUC, 83.8%; 95%CI, 66.9–93.4) but poor for the prediction of MG (AUC, 63.9%; 95%CI, 44.8–79.5)

Read more

Summary

Introduction

Thymic epithelial tumors (TET) are the most common primary tumor of the anterior mediastinum in adults and include thymomas, thymic carcinomas (TC) and thymic neuroendocrine tumors. While the metastatic tendency is low, all TET can show infiltrative growth, most commonly affecting the mediastinal pleura and the pericardium [1]. Resection status and tumor stage are the most important prognostic factors in thymomas and TCs [2]. In early stages (TNM stages I-II), thymomas are primarily resected, and achieve long, recurrence-free survival without adjuvant therapy, while advanced-stage TETs (TNM stages III-IV) require an interdisciplinary, multimodality approach comprised of an individual selection of induction chemotherapy, radical resection, adjuvant chemotherapy and sometimes radiotherapy [2]. Computed tomography (CT) and magnetic resonance imaging (MRI) are pivotal in the diagnostic workup of TETs, and preoperative biopsy may be avoided in resectable tumors. The available imaging modalities are often not able to reliably detect early stages of infiltration into adjacent structures [3]

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.